- Home
- XLO vs PYN Comparison
XLO vs PYN Comparison
Compare XLO & PYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XLO
- PYN
- Stock Information
- Founded
- XLO 2016
- PYN 2002
- Country
- XLO United States
- PYN United States
- Employees
- XLO N/A
- PYN N/A
- Industry
- XLO Biotechnology: Pharmaceutical Preparations
- PYN Investment Managers
- Sector
- XLO Health Care
- PYN Finance
- Exchange
- XLO Nasdaq
- PYN Nasdaq
- Market Cap
- XLO 35.7M
- PYN 30.1M
- IPO Year
- XLO 2021
- PYN N/A
- Fundamental
- Price
- XLO $0.66
- PYN N/A
- Analyst Decision
- XLO Buy
- PYN
- Analyst Count
- XLO 2
- PYN 0
- Target Price
- XLO $3.00
- PYN N/A
- AVG Volume (30 Days)
- XLO 341.9K
- PYN 19.9K
- Earning Date
- XLO 08-19-2025
- PYN 01-01-0001
- Dividend Yield
- XLO N/A
- PYN 5.07%
- EPS Growth
- XLO N/A
- PYN N/A
- EPS
- XLO N/A
- PYN N/A
- Revenue
- XLO $9,274,000.00
- PYN N/A
- Revenue This Year
- XLO $300.08
- PYN N/A
- Revenue Next Year
- XLO $1.87
- PYN N/A
- P/E Ratio
- XLO N/A
- PYN N/A
- Revenue Growth
- XLO N/A
- PYN N/A
- 52 Week Low
- XLO $0.62
- PYN $4.84
- 52 Week High
- XLO $1.70
- PYN $6.60
- Technical
- Relative Strength Index (RSI)
- XLO 42.53
- PYN 11.49
- Support Level
- XLO $0.62
- PYN $5.05
- Resistance Level
- XLO $0.70
- PYN $5.82
- Average True Range (ATR)
- XLO 0.04
- PYN 0.04
- MACD
- XLO -0.00
- PYN -0.60
- Stochastic Oscillator
- XLO 46.15
- PYN 0.00
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.